Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. |
Authors: |
Frerker, Nadine Raber, Kerstin Bode, Felix Skripuletz, Thomas Nave, Heike Klemann, Christian Pabst, Reinhard Stephan, Michael Schade, Jutta Brabant, Georg Wedekind, Dirk Jacobs, Roland Jörns, Anne Forssmann, Ulf Straub, Rainer H Johannes, Sigrid Hoffmann, Torsten Wagner, Leona Demuth, Hans-Ulrich von Hörsten, Stephan
|
Citation: |
Frerker N, etal., Clin Chem Lab Med. 2009;47(3):275-87. doi: 10.1515/CCLM.2009.064. |
RGD ID: |
41408336 |
Pubmed: |
PMID:19327106 (View Abstract at PubMed) |
DOI: |
DOI:10.1515/CCLM.2009.064 (Journal Full-text) |
BACKGROUND: Treatment of diabetes type 2 using chronic pharmacological inhibition of dipeptidyl peptidase 4 (DP4) still requires an in-depth analysis of models for chronic DP4 deficiency, because adverse reactions induced by some DP4 inhibitors have been described. METHODS: In the present study, a novel congenic rat model of DP4 deficiency on a "DP4-high" DA rat genetic background was generated (DA.F344-Dpp4(m)/ SvH rats) and comprehensively phenotyped. RESULTS: Similar to chronic pharmacological inhibition of DP4, DP4 deficient rats exhibited a phenotype involving reduced diet-induced body weight gain and improved glucose tolerance associated with increased levels of glucagon-like peptide-1 (GLP-1) and bound leptin as well as decreased aminotransferases and triglycerides. Additionally, DA.F344-Dpp4(m)/SvH rats showed anxiolytic-like and reduced stress-like responses, a phenomenon presently not targeted by DP4 inhibitors. However, several immune alterations, such as differential leukocyte subset composition at baseline, blunted natural killer cell and T-cell functions, and altered cytokine levels were observed. CONCLUSIONS: While this animal model confirms a critical role of DP4 in GLP-1-dependent glucose regulation, genetically induced chronic DP4 deficiency apparently also affects stress-regulatory and immuneregulatory systems, indicating that the use of chronic DP4 inhibitors might have the potential to interfere with central nervous system and immune functions in vivo.
|
|